Afficher la couverture 'Functional genetics reveals the contribution of delta opioid receptor to type 2 diabetes and beta-cell function | Meulebrouck, Sarah' en grand format
/5

0 avis

Functional genetics reveals the contribution of delta opioid receptor to type 2 diabetes and beta-cell function

Archive ouverte

Meulebrouck, Sarah | Merrheim, Judith | Queniat, Gurvan | Bourouh, Cyril | Derhourhi, Mehdi | Boissel, Mathilde | Yi, Xiaoyan | Badreddine, Alaa | Boutry, Raphaël | Leloire, Audrey | Toussaint, Bénédicte | Amanzougarene, Souhila | Vaillant, Emmanuel | Durand, Emmanuelle | Loiselle, Hélène | Huyvaert, Marlène | Dechaume, Aurélie | Scherrer, Victoria | Marchetti, Piero | Balkau, Beverley | Charpentier, Guillaume | Franc, Sylvia | Marre, Michel | Roussel, Ronan | Scharfmann, Raphaël | Cnop, Miriam | Canouil, Mickaël | Baron, Morgane | Froguel, Philippe | Bonnefond, Amélie

Edité par CCSD ; Nature Publishing Group -

International audience. Functional genetics has identified drug targets for metabolic disorders. Opioid use impacts metabolic homeostasis, although mechanisms remain elusive. Here, we explore the OPRD1 gene (encoding delta opioid receptor, DOP) to understand its impact on type 2 diabetes. Large-scale sequencing of OPRD1 and in vitro analysis reveal that loss-of-function variants are associated with higher adiposity and lower hyperglycemia risk, whereas gain-of-function variants are associated with lower adiposity and higher type 2 diabetes risk. These findings align with studies of opium addicts. OPRD1 is expressed in human islets and beta cells, with decreased expression under type 2 diabetes conditions. DOP inhibition by an antagonist enhances insulin secretion from human beta cells and islets. RNA-sequencing identifies pathways regulated by DOP antagonism, including nerve growth factor, circadian clock, and nuclear receptor pathways. Our study highlights DOP as a key player between opioids and metabolic homeostasis, suggesting its potential as a therapeutic target for type 2 diabetes.

Suggestions

Du même auteur

Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas

Archive ouverte | Meulebrouck, Sarah | CCSD

International audience. Abstract Aims/hypothesis GLIS3 encodes a transcription factor involved in pancreatic beta cell development and function. Rare pathogenic, bi-allelic mutations in GLIS3 cause syndromic neonata...

Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension

Archive ouverte | Baron, Morgane | CCSD

International audience. The G-protein-coupled receptor accessory protein MRAP2 is implicated in energy control in rodents, notably via the melanocortin-4 receptor1. Although some MRAP2 mutations have been described ...

Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas

Archive ouverte | Meulebrouck, Sarah | CCSD

International audience. Aims/hypothesis: GLIS3 encodes a transcription factor involved in pancreatic beta cell development and function. Rare pathogenic, bi-allelic mutations in GLIS3 cause syndromic neonatal diabet...

Chargement des enrichissements...